Novo Nordisk reveals post-hoc cardiovascular data for semaglutide
Novo Nordisk bolstered its heart disease data for semaglutide on Friday with additional analyses from a handful of trials.
In a pooled analysis of certain …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
